Atea Pharmaceuticals, Inc.AVIRNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank14
Studio
Year-over-Year Change

Cash generated from core business operations

Percentile
P14
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
2025$-132.03M+2.6%
2024$-135.50M-58.7%
2023$-85.39M+29.4%
2022$-120.98M-39.1%
2021$-87.00M-129.3%
2020$296.73M+2415.7%
2019$-12.81M-62.0%
2018$-7.91M-